Quantcast

Latest Sirolimus Stories

2011-10-24 09:25:24

CK1 protein in cancer cells identified as possible future therapeutic target Researchers from the NYU Cancer Institute, an NCI-designated cancer center at NYU Langone Medical Center, have identified a cell cycle-regulated mechanism behind the transformation of normal cells into cancerous cells. The study shows the significant role that protein networks can play in a cell leading to the development of cancer. The study results, published in the October 21 issue of the journal Molecular...

2011-10-21 09:09:05

The condition tuberous sclerosis, due to mutation in one of two tumor suppressor genes, TSC1 or TSC2, causes the growth of non-malignant tumors throughout the body and skin. These tumors can be unsightly and cause serious damage to organs. Growth of tumors in the brain may cause seizures and in the kidney, liver or heart, tumors can disrupt normal function, to the extent of causing the organ to fail. New research published in BioMed Central's open access journal Cell and Bioscience shows that...

2011-08-30 12:28:35

Results from the Bern-Rotterdam cohort study Results of the independently-funded Bern-Rotterdam cohort study provide robust evidence of an "important" reduction in overall and very late stent thrombosis. The reduction in incidence was found when a newer generation everolimus-eluting stent (EES) was compared with early generation drug-eluting stents (DES) at long-term follow-up. "The near elimination of stent thrombosis observed between one and four years after implantation shows that...

2011-08-29 20:19:10

A specific inhibitor of the small regulatory RNA-molecule “microRNA-100” can be used to stimulate the growth of new blood vessels, if a major artery is chronically occluded. This is the result of a recent experimental study carried out at the University Hospital Freiburg in Germany and funded by the German Research Foundation. In an animal model of peripheral artery disease, blood flow to the lower leg was significantly improved after treatment with the so-called...

2011-08-16 08:00:00

HONG KONG, Aug. 16, 2011 /PRNewswire/ -- OrbusNeich today announced that the that the company's Genous Stent showed no significant difference in the rate of target vessel failure (TVF) at two years compared to the Taxus Liberte(TM) paclitaxel-eluting stent in patients with de novo coronary artery lesions carrying a high risk for restenosis. The two-year follow-up data from the prospective, randomized TRIAS pilot study were published in Catheterization and Cardiovascular Interventions....

2011-07-29 14:38:29

Combination of two immunosuppressive drugs led to less organ rejection, better organ health after transplant For the thousands of patients who receive kidney transplants in the United States each year, preventing organ rejection without compromising other aspects of health requires a delicate balance of medications. Immunosuppresive drugs that protect transplanted organs can also cause serious side effects, including compromising patients' immunity to infection, cancer, and other threats....

2011-07-26 12:10:00

DURHAM, N.C., July 26, 2011 /PRNewswire/ -- Micell Technologies, Inc. today announced that it has completed patient enrollment in its DESSOLVE II CE Mark clinical study of the MiStent® Drug-Eluting Coronary Stent System. The MiStent DES is an ultra-thin drug-eluting stent distinguished by a rapid-absorbing drug/polymer coating formulation. Enrollment of 183 patients across 26 study centers throughout Europe and New Zealand was accomplished ahead of schedule. Micell...

2011-07-18 10:46:00

HONG KONG, July 18, 2011 /PRNewswire/ -- Data from high-risk patients requiring early discontinuation of dual antiplatelet therapy (DAPT) due to nondeferrable, non-cardiac surgery show good short- and long-term clinical and safety outcomes following treatment with OrbusNeich's Genous Stent, according to a study published online on the journal Minerva Cardioangiologica's website. In the single-center study, patients treated with the Genous endothelial progenitor cell (EPC) capture stent...


Word of the Day
barratry
  • The offense of persistently instigating lawsuits, typically groundless ones.
  • An unlawful breach of duty on the part of a ship's master or crew resulting in injury to the ship's owner.
  • Sale or purchase of positions in church or state.
This word ultimately comes from the Old French word 'barater,' to cheat.
Related